Intellia Therapeutics, Inc. (FRA:38I)
8.10
+1.11 (15.88%)
At close: Nov 28, 2025
Intellia Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 193.39 | 189.18 | 226.75 | 523.51 | 123.41 | 160.02 | Upgrade |
Short-Term Investments | 317.66 | 412.33 | 685.48 | 669.12 | 625.28 | 437.35 | Upgrade |
Cash & Short-Term Investments | 511.04 | 601.52 | 912.22 | 1,193 | 748.69 | 597.37 | Upgrade |
Cash Growth | -22.35% | -34.06% | -23.51% | 59.29% | 25.33% | 113.56% | Upgrade |
Receivables | 11.05 | 8.52 | 36.46 | 3.77 | 2.03 | 2.13 | Upgrade |
Prepaid Expenses | 59.85 | 29.83 | 47.55 | 20.41 | 18.58 | 14.32 | Upgrade |
Restricted Cash | - | - | - | - | - | 2.7 | Upgrade |
Other Current Assets | - | - | 2.1 | - | - | - | Upgrade |
Total Current Assets | 581.94 | 639.86 | 998.33 | 1,217 | 769.3 | 616.52 | Upgrade |
Property, Plant & Equipment | 138.3 | 246.67 | 148.14 | 161 | 100.11 | 55.06 | Upgrade |
Long-Term Investments | 188.34 | 287.09 | 136.39 | 126.59 | 420.29 | 0.16 | Upgrade |
Other Long-Term Assets | 16.69 | 17.39 | 18.12 | 15.73 | 4.76 | 4.59 | Upgrade |
Total Assets | 925.28 | 1,191 | 1,301 | 1,520 | 1,294 | 676.32 | Upgrade |
Accounts Payable | 13.26 | 14.59 | 7.45 | 5.15 | 9.65 | 10.46 | Upgrade |
Accrued Expenses | 40.84 | 55.36 | 60.13 | 60.88 | 43.31 | 25.55 | Upgrade |
Current Portion of Leases | 27.38 | 20.25 | 18.6 | 16.69 | 9.11 | 5.7 | Upgrade |
Current Unearned Revenue | 12.25 | 20.66 | 22.14 | 43.84 | 63.76 | 22.54 | Upgrade |
Other Current Liabilities | - | - | 6.89 | - | - | - | Upgrade |
Total Current Liabilities | 93.73 | 110.85 | 115.21 | 126.55 | 125.83 | 64.25 | Upgrade |
Long-Term Leases | 70.59 | 189.95 | 96.75 | 114.02 | 64.91 | 33.61 | Upgrade |
Long-Term Unearned Revenue | 12.54 | 18.26 | 38.85 | 19.93 | 63.48 | 51.39 | Upgrade |
Other Long-Term Liabilities | - | - | - | 24.03 | - | - | Upgrade |
Total Liabilities | 176.85 | 319.06 | 250.81 | 284.53 | 254.22 | 149.25 | Upgrade |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade |
Additional Paid-In Capital | 3,242 | 3,049 | 2,711 | 2,420 | 1,746 | 962.17 | Upgrade |
Retained Earnings | -2,494 | -2,177 | -1,658 | -1,177 | -703 | -435.11 | Upgrade |
Comprehensive Income & Other | 0.99 | 0.61 | -2.26 | -7.46 | -2.63 | 0 | Upgrade |
Total Common Equity | 748.42 | 871.96 | 1,050 | 1,236 | 1,040 | 527.07 | Upgrade |
Shareholders' Equity | 748.42 | 871.96 | 1,050 | 1,236 | 1,040 | 527.07 | Upgrade |
Total Liabilities & Equity | 925.28 | 1,191 | 1,301 | 1,520 | 1,294 | 676.32 | Upgrade |
Total Debt | 97.97 | 210.2 | 115.35 | 130.7 | 74.02 | 39.31 | Upgrade |
Net Cash (Debt) | 571.89 | 651.53 | 896.74 | 1,131 | 1,012 | 558.07 | Upgrade |
Net Cash Growth | -32.16% | -27.34% | -20.73% | 11.78% | 81.34% | 109.72% | Upgrade |
Net Cash Per Share | 5.45 | 6.59 | 10.10 | 14.70 | 14.28 | 9.97 | Upgrade |
Filing Date Shares Outstanding | 115.83 | 103.52 | 96.11 | 88.02 | 74.67 | 67.73 | Upgrade |
Total Common Shares Outstanding | 115.79 | 102.03 | 93 | 87.1 | 74.49 | 66.23 | Upgrade |
Working Capital | 488.22 | 529.01 | 883.12 | 1,090 | 643.47 | 552.26 | Upgrade |
Book Value Per Share | 6.46 | 8.55 | 11.29 | 14.19 | 13.97 | 7.96 | Upgrade |
Tangible Book Value | 748.42 | 871.96 | 1,050 | 1,236 | 1,040 | 527.07 | Upgrade |
Tangible Book Value Per Share | 6.46 | 8.55 | 11.29 | 14.19 | 13.97 | 7.96 | Upgrade |
Machinery | - | 71.97 | 67.59 | 56.33 | 43.34 | 32.7 | Upgrade |
Leasehold Improvements | - | 3.2 | 3.13 | 3.07 | 2.19 | 1.52 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.